Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.

A new contraceptive spray currently in clinical trials is showing positive results in patients, according to Australian drug maker Acrux. The company’s Nestorone MDTS is a fourth-generation progestin contraceptive that has no androgenic hormonal effects and a good safety profile. The spray is a small, hand-held, easy-to-use spray designed to provide an easy and convenient means to deliver a preset dose of therapeutic drug directly to the skin. It is being touted by its maker as a “better choice” for women using hormonal contraceptive pills or patches.

Read the rest of this entry »

A British survey suggests one in three women spend no more than five minutes selecting a suitable contraceptive method to use, according to Medical News Today. The report, conducted by Family Planning Association, is part of the organization’s Finding the Perfect Partner (Choose What You Use) campaign to help reduce unplanned pregnancy and abortion, and to promote greater control over contraceptive choice among women and health professionals. It found that despite the seemingly little care women put into the decision of what type of birth control to use, nearly half have had an unwanted pregnancy scare.

Read the rest of this entry »

Students at Texas Christian University (TCU) now have access to more affordable contraceptives through the university’s Health Center, according to the TCU news Web site Daily Skiff. The Health Center negotiated a contract with drug companies to offer the discounted rates to students requesting contraceptives such as Ortho Tri-Cyclen and the Ortho Evra Contraceptive Transdermal Patch.

Read the rest of this entry »

Drug maker Johnson & Johnson is recalling another one of its patches, the Duragesic fentanyl pain patch. According to BNet Business Network, the fentanyl patch is highly addictive and has been linked to deaths caused by the patches to leak too much medicine into the body.

Read the rest of this entry »

Public Citizen, an 80,000-member nonprofit organization dedicated to consumer advocacy, petitioned the FDA to ban Johnson & Johnson’s contraceptive patch Ortho Evra (ethinyl estradiol/norelgestromin). The organization requested complete removal of the contraceptive within 6 months.

Read the rest of this entry »

The FDA approved a label change to Johnson & Johnson’s Ortho Evra birth control patch on January 18, 2008. The patch has been known to cause blood clots which can lead to pulmonary embolism and death. The label change comes after testing revealed women on the patch between the ages of 15-44 are at a higher risk for pulmonary embolism.

Read the rest of this entry »

In a 5-2 decision, the Ohio Supreme Court Thursday morning upheld the constitutionality of a 2004 law capping damages for pain, suffering, and other non-economic claims in personal injury and other lawsuits.

Read the rest of this entry »

Ortho Evra manufacturer, Johnson & Johnson, recently settled a lawsuit with the family of a 14-year-old girl killed by the defective birth control patch. The case is just one of many Ortho Evra lawsuits settled by Johnson & Johnson prior to going trial.

Read the rest of this entry »

Johnson & Johnson agreed to pay $1.25 million to settle a lawsuit over the death of a 14-year-old girl who used the company’s Ortho Evra birth-control patch, according to court records.

Read the rest of this entry »